You are here

Article Text

Article menu
Download PDFPDF
Clinical round-up
Clinical round-up
  1. Lewis J Haddow1,
  2. Sophie Herbert2
  1. 1Department of Infection & Population Health, Centre for Sexual Health and HIV Research, University College London, London, UK
  2. 2Department of Genitourinary Medicine, Nottingham University Hospitals, London, UK
  1. Correspondence to Dr Lewis J Haddow, Department of Infection & Population Health, Centre for Sexual Health and HIV Research, University College London, 4th floor, Mortimer Market Centre, Capper Street, London WC1E 6JB, UK; lewis.haddow{at}ucl.ac.uk

https://doi.org/10.1136/sextrans-2015-052366

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    An effective treatment for recurrent bacterial vaginosis

    Women with recurrent vaginal infections often take regular, repeated doses of antimicrobials to prevent further episodes. Unfortunately, metronidazole treatment of bacterial vaginosis (BV) may lead to vulvovaginal candidiasis (VVC). In a randomised placebo-controlled trial in Kenya and the USA, HIV-negative women with either of these infections or trichomoniasis were enrolled in a study of a combined miconazole/metronidazole vaginal suppository, given for five consecutive days every month for a year.1 The intervention reduced the risk of laboratory-proven BV, the most common vaginal infection in the study, by 35%. Unfortunately, there was no effect on subsequent rates of either VVC or trichomoniasis, but it is reassuring that the treatment did not lead to an increase in VVC rates. The report does not provide a breakdown of the results according to which of the three infections was present at baseline, which would have been useful additional clinical information.

    Expect the unexpected: some immunological effects of HIV

    The Beijing PRIMO cohort is a large prospective study of HIV-negative men who have sex …

    View Full Text

    Footnotes

    • Contributors The article was drafted by LJH and edited by SH.

    • Competing interests None declared.

    • Provenance and peer review Commissioned; internally peer reviewed.